<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1998, the Tunisian team of the 'Centre National de Greffe de Moelle Osseuse' initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia </plain></SENT>
<SENT sid="1" pm="."><plain>As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants </plain></SENT>
<SENT sid="2" pm="."><plain>The median age was 19 years (range 2-49 years) </plain></SENT>
<SENT sid="3" pm="."><plain>The main indications were <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n=106, 36%), <z:hpo ids='HP_0001909'>leukemia</z:hpo> and nonmalignant disorders (n=153, 51%), Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (n=26, 9%) and other nonmalignant disorders (n=14, 4%) </plain></SENT>
<SENT sid="4" pm="."><plain>Preparative regimens depended on indication </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> donors were HLA geno-identical </plain></SENT>
<SENT sid="6" pm="."><plain>The stem cell sources were BM (87%) and PBSCs (13%) </plain></SENT>
<SENT sid="7" pm="."><plain>At the time of analysis, 200 patients (67%) were alive after a median follow-up of 42 months (range 3-112 months) </plain></SENT>
<SENT sid="8" pm="."><plain>The overall TRM rate was 17% </plain></SENT>
<SENT sid="9" pm="."><plain>Outcome depended on indication </plain></SENT>
<SENT sid="10" pm="."><plain>According to our results, allogeneic HSCT is potentially curative for <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e>, but it is a toxic approach for malignant disorders </plain></SENT>
</text></document>